Skip to content
AnalystLens

Edwards Lifesciences 8-K Report, Regulation FD Disclosure (Sep 3, 2024)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed September 3, 2024
Period End
September 3, 2024
Security
EW
In the record · 2016–202610-K1110-Q328-K88

EW filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 88 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’18Jun ’18
  2. Leadership change8-K · Dec ’22Dec ’22
  3. Leadership change8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed September 3, 2024. Cited figures are marked; the original filing is the authoritative source.

On September 3, 2024, Edwards Lifesciences (EW) filed an 8-K announcing that it completed the previously disclosed sale of its Critical Care product group to Becton, Dickinson and Company (BD) for $4.2 billiona in an all-cash transaction.

Management said the net proceeds will fund strategic initiatives, including previously announced acquisitions and share repurchases. The divestiture leaves Edwards focused as a structural heart company. Alongside the closing, the Board authorized an additional $1.5 billionb in share repurchases.

Edwards also entered into a $500 millionc accelerated share repurchase (ASR) agreement and, earlier in August, had already repurchased $500 million of stock through a 10b5-1 plan and open-market purchases. After the latest $1 billion repurchase, the company reports $1.4 billion of remaining authorization for future buybacks. CEO Bernard Zovighian framed the sale as sharpening the company's focus on TAVR, transcatheter mitral and tricuspid therapy (TMTT), surgical leadership, and implantable therapies for aortic regurgitation and non-valvular structural heart disease.

The filing itself is brief; the press release notes the company will present its strategy and outlook at the Wells Fargo Healthcare Conference on September 5, 2024. The filing contains no financial results, so investors should look to the accompanying materials and subsequent filings for the financial impact of the divestiture.

02—Key points

Key Highlights

  1. Completed the sale of the Critical Care product group to BD for $4.2 billion in cash.
  2. Board approved an additional $1.5 billion share repurchase authorization.
  3. Entered into a $500 million accelerated share repurchase agreement.
  4. Repurchased $500 million of common stock in August via a 10b5-1 plan and open-market purchases.
  5. Following the latest $1 billion in repurchases, Edwards has $1.4 billion of remaining authorization.
  6. Management is refocusing the company on structural heart, with TAVR, TMTT, and surgical as priorities.
  7. CEO to present strategy and outlook at the Wells Fargo Healthcare Conference on September 5, 2024.

03—Questions

Frequently Asked Questions

  1. How much did Edwards receive from the Critical Care sale?

    Edwards sold the Critical Care product group to BD for $4.2 billion in an all-cash transaction. The filing does not break out net proceeds after taxes, fees, or other adjustments.

  2. How will Edwards use the proceeds?

    The company says the net proceeds will fund strategic initiatives, including previously announced acquisitions and share repurchases.

  3. How much stock buyback capacity does Edwards have now?

    After the $1 billion in recent repurchases (the $500 million ASR plus the earlier August buybacks), Edwards reports $1.4 billion of remaining authorization for future share repurchases.

  4. Why is Edwards divesting Critical Care?

    Management says the sale sharpens the company's focus as a structural heart innovator, concentrating investment on TAVR, TMTT, surgical leadership, and implantable therapies for aortic regurgitation and non-valvular structural heart disease.

  5. Does this filing include financial results or guidance?

    No. The 8-K covers the transaction closing and capital return actions only. The filing does not provide financial results, updated guidance, or the financial impact of the divestiture; investors should look to the company's earnings releases and periodic reports for those details.

04—Continue

← View all 8-K filings